Piper Jaffray Cuts Price Target on Zumiez, Inc. (ZUMZ) Following 4Q Report

Go back to Piper Jaffray Cuts Price Target on Zumiez, Inc. (ZUMZ) Following 4Q Report

Jefferies Remains Sidelined on Zumiez, Inc. (ZUMZ) Following 4Q Results

March 11, 2016 8:49 AM EST

Jefferies reiterated a Hold rating on Zumiez, Inc. (NASDAQ: ZUMZ), and raised the price target to $20.00 (from $17.00), as the company's 4Q results exceed expectations. Good expense control helped ZUMZs 4Q EPS come in 4c ahead of consensus expectations. However, the struggles... More

After-Hours Stock Movers 03/10: (SSKN) (ULTA) (FNSR) Higher; (FXCM) (ZUMZ) (LOCO) Lower (more...)

March 10, 2016 6:02 PM EST

STRATA Skin Sciences, Inc. (NASDAQ: SSKN) 35.2% HIGHER; announced today that the U.S. Food and Drug Administration (FDA) approved STRATAs PMA supplement for the MelaFind System.

FXCM Inc. (NYSE: FXCM) 18.6% LOWER; Leucadia National Corporation (NYSE: LUK) and FXCM Inc. (NYSE: FXCM) announced that they have entered into a memorandum of understanding (the MOU) to amend the terms of their Amended and Restated Credit Agreement (the Credit Agreement), and... More

Zumiez, Inc. (ZUMZ) Reports In-Line Q4 EPS

March 10, 2016 4:07 PM EST

Zumiez, Inc. (NASDAQ: ZUMZ) reported Q4 EPS of $0.50, in-line with the analyst estimate of $0.50. Revenue for the quarter came in at $242.4 million versus the consensus estimate of $241.1 million.

Comparable sales for the 13-week period ended January 30, 2016 decreased 9.5% compared to an 8.3% increase for the 13-week period... More

Trading Radar for 3/10: Dollar General (DG), Canadian Solar (CSIQ), Plug Power (PLUG), Veifone (PAY) Report

March 9, 2016 2:56 PM EST

The Trading Radar highlights key earnings and economic announcements for the next trading session:

Before Markets Open:
Economics:
8:30am EST

Initial Claims - Street sees 275kContinuing Claims - Street sees 2.251M

Earnings:

BioLineRx (Nasdaq: BLRX) - consensus loss $0.06
CECO Environmental (Nasdaq: CECE) - consensus EPS $0.21
Canadian Solar (Nasdaq: CSIQ) - consensus EPS $0.76
Cantel Medical (NYSE: CMN) - consensus EPS $0.34
Cardiome Pharma (Nasdaq:... More